Zacks Investment Research downgraded shares of TRANSCEPT PHARM (TSPT) from OUTPERFORM to NEUTRAL on November 13, 2013, with a target price of $4.10.
Transcept Pharmaceuticals, Inc., formerly Novacea, Inc. is a biopharmaceutical company focused on in-licensing, developing and commercializing therapies for the treatment of cancer. The Company's product portfolio features two clinical-stage oncology product candidates with worldwide rights, Asentar and AQ4N, each of which is a potential treatment for certain types of cancer. The Company continues to be primarily involved in performing research and development activities, hiring personnel, licensing new products, and raising capital to support and expand these activities. Its goal is to become a leading specialty pharmaceutical company addressing important therapeutic needs in psychiatry and sleep medicine.
Get all Zacks Research Reports and be alerted to fast-breaking buy and sell opportunities every trading day.
To get a free copy of the research report on TRANSCEPT PHARM (TSPT),
click here.
For more information about research offerings from Zacks Investment Research, visit
Zacks.com .
Be the first to comment